BP
BMY icon

Ballentine Partners’s Bristol-Myers Squibb BMY Stock Holding History

Ballentine Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Buy
41,874
+3,090
+8% +$177K 0.03% 189
2026
Q1 		$2.35M Buy
38,784
+997
+3% +$58.1K 0.03% 178
2025
Q4 		$2.04M Buy
37,787
+1,332
+4% +$64.1K 0.03% 192
2025
Q3 		$1.64M Sell
36,455
-1,777
-5% -$83K 0.02% 231
2025
Q2 		$1.77M Sell
38,232
-2,554
-6% -$125K 0.03% 215
2025
Q1 		$2.49M Buy
40,786
+233
+0.6% +$13.6K 0.04% 156
2024
Q4 		$2.29M Buy
40,553
+1,508
+4% +$84.3K 0.04% 156
2024
Q3 		$2.02M Buy
39,045
+3,399
+10% +$159K 0.03% 172
2024
Q2 		$1.48M Sell
35,646
-11,745
-25% -$526K 0.03% 201
2024
Q1 		$2.57M Buy
47,391
+15,454
+48% +$787K 0.05% 127
2023
Q4 		$1.64M Sell
31,937
-9,395
-23% -$493K 0.03% 171
2023
Q3 		$2.4M Buy
41,332
+1,116
+3% +$68.4K 0.06% 106
2023
Q2 		$2.57M Buy
40,216
+8,344
+26% +$560K 0.06% 104
2023
Q1 		$2.21M Sell
31,872
-4,283
-12% -$302K 0.06% 120
2022
Q4 		$2.6M Buy
36,155
+1,711
+5% +$129K 0.08% 94
2022
Q3 		$2.45M Buy
34,444
+2,921
+9% +$212K 0.08% 82
2022
Q2 		$2.43M Buy
31,523
+534
+2% +$40.7K 0.09% 85
2022
Q1 		$2.26M Buy
30,989
+241
+0.8% +$16.2K 0.07% 101
2021
Q4 		$1.92M Buy
30,748
+751
+3% +$44.1K 0.06% 111
2021
Q3 		$1.78M Sell
29,997
-1,295
-4% -$85.3K 0.06% 106
2021
Q2 		$2.09M Buy
31,292
+51
+0.2% +$3.33K 0.07% 94
2021
Q1 		$1.97M Sell
31,241
-1,884
-6% -$117K 0.07% 91
2020
Q4 		$2.06M Sell
33,125
-3,349
-9% -$206K 0.08% 87
2020
Q3 		$2.2M Buy
36,474
+1,519
+4% +$91.4K 0.1% 80
2020
Q2 		$2.06M Sell
34,955
-935
-3% -$55.9K 0.1% 81
2020
Q1 		$2M Sell
35,890
-5,242
-13% -$320K 0.12% 74
2019
Q4 		$2.64M Buy
41,132
+7,897
+24% +$452K 0.12% 74
2019
Q3 		$1.69M Buy
33,235
+1,540
+5% +$72.4K 0.08% 103
2019
Q2 		$1.44M Buy
31,695
+1,295
+4% +$60.3K 0.07% 116
2019
Q1 		$1.45M Sell
30,400
-437
-1% -$21.8K 0.08% 95
2018
Q4 		$1.6M Buy
30,837
+18,714
+154% +$1.01M 0.09% 79
2018
Q3 		$752K Buy
12,123
+678
+6% +$40.2K 0.04% 157
2018
Q2 		$633K Sell
11,445
-181
-2% -$9.78K 0.04% 161
2018
Q1 		$736K Sell
11,626
-317
-3% -$20.4K 0.04% 144
2017
Q4 		$732K Sell
11,943
-2,273
-16% -$142K 0.04% 151
2017
Q3 		$905K Buy
14,216
+54
+0.4% +$3.15K 0.05% 130
2017
Q2 		$793K Sell
14,162
-869
-6% -$47.3K 0.06% 148
2017
Q1 		$818K Sell
15,031
-1,023
-6% -$56.1K 0.06% 84
2016
Q4 		$961K Buy
16,054
+249
+2% +$13.6K 0.07% 70
2016
Q3 		$851K Sell
15,805
-513
-3% -$33K 0.07% 67
2016
Q2 		$1.2M Sell
16,318
-160
-1% -$11.3K 0.1% 55
2016
Q1 		$1.05M Buy
16,478
+4,270
+35% +$269K 0.09% 64
2015
Q4 		$840K Buy
12,208
+471
+4% +$31.1K 0.08% 64
2015
Q3 		$695K Buy
11,737
+262
+2% +$16.6K 0.07% 68
2015
Q2 		$763K Sell
11,475
-179
-2% -$11.8K 0.07% 66
2015
Q1 		$748K Buy
11,654
+700
+6% +$43.8K 0.07% 68
2014
Q4 		$647K Buy
10,954
+153
+1% +$8.63K 0.07% 74
2014
Q3 		$549K Sell
10,801
-11
-0.1% -$549 0.07% 75
2014
Q2 		$520K Sell
10,812
-441
-4% -$21.7K 0.06% 76
2014
Q1 		$584K Buy
11,253
+49
+0.4% +$2.61K 0.07% 68
2013
Q4 		$596K Buy
11,204
+122
+1% +$6.21K 0.07% 70
2013
Q3 		$513K Buy
11,082
+3,920
+55% +$172K 0.06% 71
2013
Q2 		$320K Buy
+7,162
New +$311K 0.04% 87

Other funds holding BMY

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
ORIO
Old Republic International (ORI) Chicago, Illinois $2.67B AUM 26.94% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Ballentine Partners's BMY Position: Q2 2026 in Review

Ballentine Partners increased its Bristol-Myers Squibb (BMY) stake by 8% in Q2 2026, buying an estimated $177K and bringing the position to 41,874 shares worth $2.41M. The position accounts for 0.03% of the portfolio, ranked #189.

Ballentine Partners first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.64M in Q4 2019. 440 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Ballentine Partners held 41,874 shares of Bristol-Myers Squibb worth $2.41M as of Q2 2026.
  • Ballentine Partners bought 3,090 Bristol-Myers Squibb shares in Q2 2026, an estimated $177K.
  • Bristol-Myers Squibb made up 0.03% of Ballentine Partners's portfolio in Q2 2026, its #189 holding.
  • Ballentine Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
  • Ballentine Partners's Bristol-Myers Squibb position peaked at $2.64M in Q4 2019.
  • 440 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.